Provided by Tiger Fintech (Singapore) Pte. Ltd.

Taysha Gene Therapies, Inc.

1.24
+0.06005.08%
Post-market: 1.21-0.0300-2.42%19:01 EDT
Volume:983.01K
Turnover:1.19M
Market Cap:254.20M
PE:-3.47
High:1.26
Open:1.19
Low:1.13
Close:1.18
Loading ...

Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham

Dow Jones
·
10 Apr

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

TIPRANKS
·
04 Apr

Press Release: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
04 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple

Reuters
·
01 Apr

US STOCKS-S&P 500, Nasdaq slip as investors await major tariff news

Reuters
·
01 Apr

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet

Benzinga
·
31 Mar

Shares of Gene Therapy Makers and Developers Fall After Report That FDA Official Peter Marks Has Resigned

THOMSON REUTERS
·
31 Mar

Solid Biosciences Down 10.5%, Taysha Gene Therapies Down 14%

THOMSON REUTERS
·
31 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Gene therapy cos, gold miners, chipmakers

Reuters
·
31 Mar

BUZZ-Gene therapy makers slide on reports that FDA official Peter Marks resigns

Reuters
·
31 Mar

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

TIPRANKS
·
07 Mar

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
07 Mar

Buy Rating Reiterated for Taysha Gene Therapies Amid Positive Clinical Data and Strong Financial Position

TIPRANKS
·
02 Mar

Taysha Gene Therapies’ Positive Earnings Call Highlights

TIPRANKS
·
28 Feb

Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position

TIPRANKS
·
27 Feb

Taysha Gene Therapies Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
27 Feb

Q4 2024 Taysha Gene Therapies Inc Earnings Call

Thomson Reuters StreetEvents
·
27 Feb

Taysha Gene Therapies Reports 2024 Financial Results

TIPRANKS
·
27 Feb

Taysha Gene Therapies Is Maintained at Buy by Chardan Capital

Dow Jones
·
27 Feb